Blog
RSS FeedPosted by Michael Wonder on 13 Nov 2018
Canada's HTA agency releases report on international biosimilar policies
8 November 2018 - The Canadian Agency for Drugs and Technologies in Health (CADTH), the Canadian entity responsible for health ...
Posted by Michael Wonder on 12 Nov 2018
Biosimilar drugs promise to slash health care costs in rich countries
8 November 2018 - The world's top-selling drug now faces biosimilars that are 80% cheaper. ...
Posted by Michael Wonder on 05 Nov 2018
RFP - supply of etanercept
5 November 2018 - PHARMAC invites proposals for the supply of etanercept in New Zealand. ...
Posted by Michael Wonder on 23 Oct 2018
Biosimilar adalimumab: a landmark for NHS medicines optimisation
23 October 2018 - The NHS’s bid to improve patient outcomes and save money by switching costly biological drugs for ...
Posted by Michael Wonder on 06 Oct 2018
Global moves to reduce the future cost of publicly funded medicines
5 October 2018 - The most significant advances in medical treatments are being made with biological products that are significantly ...
Posted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...
Posted by Michael Wonder on 25 Sep 2018
Decision to change the funded brand of epoetin alfa
24 September 2018 - PHARMAC is pleased to announce the approval of an agreement with Novartis for the supply of ...
Posted by Michael Wonder on 18 Sep 2018
Changes to TGA/PBAC parallel processing arrangements for biosimilar medicines
18 September 2018 - Submissions requesting the listing of a new biosimilar medicine are no longer eligible to be submitted under ...
Posted by Michael Wonder on 06 Sep 2018
UK lags behind most of Europe in access to biologics for patients with rheumatoid arthritis
4 September 2018 - Global leader in biosimilars, Celltrion Healthcare announces support for the easing of initiation boundaries for biologics that ...
Posted by Michael Wonder on 03 Sep 2018
Biosimilar awareness initiative – literature review
3 September 2018 - The biosimilar literature review update for the period March 2018 to May 2018 is now available. ...
Posted by Michael Wonder on 30 Aug 2018
Renflexis (infliximab for injection) added to British Columbia's Provincial Drug Plan for all approved indications
22 August 2018 - Renflexis has been added to drug formulary for the treatment of adult and paediatric Crohn's disease and ...
Posted by Michael Wonder on 21 Aug 2018
Proposal to change the funded brand of epoetin alfa
21 August 2018 - PHARMAC is seeking feedback on a proposed change to the funded brand of epoetin alfa [erythropoietin ...
Posted by Michael Wonder on 10 Aug 2018
Biosimilars for insulin: a cost-saving alternative?
11 August 2018 - The expiry of patents on an insulin analogue has opened the market to the production of biosimilar ...
Posted by Michael Wonder on 07 Aug 2018
Government looks to include biosimilars in price controls
7 August 2018 - The government has launched consultation on proposed changes to the statutory scheme for pharmaceutical pricing that ...
Posted by Michael Wonder on 02 Aug 2018
NHS saved £324 million by switching to biosimilars and generics
2 August 2018 - The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar ...